Table 2.
Treatment-related adverse events occurring in ≥10% of patients
| Adverse event | Any grade, n (%) |
Grade 3 or 4, n (%) |
|---|---|---|
| Fatigue | 59 (61) | 10 (10) |
| Diarrhea | 51 (53) | 7 (7) |
| Nausea | 38 (39) | 3 (3) |
| Skin discoloration | 37 (38) | 0 (0) |
| Hand-foot syndrome | 36 (37) | 7 (7) |
| Hypertension | 28 (29) | 16 (16) |
| Stomatitis | 28 (29) | 2 (2) |
| Asymptomatic increase in lipase* |
26 (27) | 13 (13) |
| Vomiting | 20 (21) | 1 (1) |
| Dermatitis | 19 (20) | 0 (0) |
| Increased serum creatinine phosphokinase |
18 (19) | 1 (1) |
| Taste disturbance | 18 (19) | 0 (0) |
| Hypothyroidism | 17 (18) | 0 (0) |
| Dyspepsia | 15 (15) | 1 (1) |
| Increased serum amylase | 15 (15) | 4 (4) |
| Anemia | 14 (14) | 3 (3) |
| Flatulence | 14 (14) | 0 (0) |
| Headache | 14 (14) | 2 (2) |
| Decreased hemoglobin | 13 (13) | 3 (3) |
| Glossodynia | 13 (13) | 0 (0) |
| Limb pain | 13 (13) | 0 (0) |
| Decreased leukocyte count | 12 (12) | 3 (3) |
| Hair color changes | 11 (11) | 0 (0) |
| Paresthesia | 11 (11) | 0 (0) |
| Abdominal pain | 10 (10) | 3 (3) |
| Anorexia | 10 (10) | 1 (1) |
| Decreased neutrophil count | 10 (10) | 4 (4) |
*
Grade 3/4 lipase increase was accompanied by pancreatitis in one patient.